middle.news
Prescient clears PTX-100 review hurdle with A$6 million funding secured
9:39am on Tuesday 13th of October, 2026 AEDT
•
Biotechnology
Read Story
Prescient clears PTX-100 review hurdle with A$6 million funding secured
9:39am on Tuesday 13th of October, 2026 AEDT
Key Points
20 evaluable CTCL patients enrolled across two dosing arms
Dose Optimisation Committee review scheduled for December 2026
A$6.0 million raise lifts pro forma cash to A$11.8 million
Total enrolment reached 29 patients against a 40-patient evaluable target
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Prescient Therapeutics (ASX:PTX)
OPEN ARTICLE